PulseAugur
EN
LIVE 21:38:48
中文(ZH) 一品红：全资子公司创新药APH03867片获得临床试验注册申请受理

Yipin Hong subsidiary's drug candidate APH03867 accepted for clinical trials

By PulseAugur Editorial · [1 sources] ·

Yipin Hong's subsidiary, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for its clinical trial application for the innovative drug APH03867. This marks a significant step in the drug's development process. Separately, Shanghai Yancheng Trading Co., Ltd. saw changes in its leadership, with Kelly Zong appointed as the legal representative and manager, and Zhejiang Hongyi Holding Group Co., Ltd. as the sole shareholder. AI

RANK_REASON The cluster reports on a drug candidate receiving regulatory acceptance for clinical trials, which falls under research and development milestones. [lever_c_demoted from research: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Yipin Hong subsidiary's drug candidate APH03867 accepted for clinical trials

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
The cluster reports on a drug candidate receiving regulatory acceptance for clinical trials, which falls under research and development milestones. [lever_c_demoted from research: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
93 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Yipin Hong: Wholly-owned subsidiary's innovative drug APH03867 tablets receive clinical trial registration application acceptance

    36氪获悉，一品红公告，全资子公司广州一品红制药有限公司自主研发的创新药物APH03867片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。

RELATED ENTITIES

RELATED TOPICS